Colleen Riley

Colleen Riley

SVP, Chief Technology Officer

Colleen Riley serves as the SVP, Chief Technology Officer for embecta. Previously, Colleen was the Senior Vice President of Innovation and Development for Terumo Blood and Cell Technologies. Under Colleen’s leadership she advanced both existing and new product platforms beyond traditional scope of medical devices and therapy manufacturing to include services, software, and data management. These advancements drove continued growth throughout the particularly challenging COVID-19 pandemic.

Prior to that role, she served as Vice President Science and Technology and Vice President Regulatory Affairs and Compliance at Stryker Orthopedics. During this tenure, she led a regulatory transformation that delivered the pivotal Mako robotic clearances and expanded 3D printing capabilities. These initiatives led to optimized orthopedic implant design, improved functional outcomes and patient satisfaction, and drove market-leading growth.  She also served as Vice President, Global Research for Novartis, AG, and Chief Operation Officer for Nexis Vision Inc. In both these roles, she led the organization into new white space, high growth opportunities, significantly increasing the value of their respective portfolios.

Colleen held several roles of increased responsibility at Johnson & Johnson Vision, including Vice President, Professional Development and Medical Affairs. Additionally, she was lead designer and developer of new product pipelines across multiple therapeutic categories. This included category altering products for both developed and emerging markets. Her efforts helped generate more than $2 billion in worldwide sales and market-leading growth.

A Doctor of Optometry, Colleen started her professional career in private practice, before joining the Indiana University School of Optometry as Clinical Faculty, Residency Program Supervisor and Co-Director of the Clinic.  Colleen earned a Bachelor of Arts in Chemistry, a Master of Science in Physiological Optics and an OD, Doctor of Optometry, degree from Indiana University.

    Forward Looking Statement

    The information included on this website and other information provided from time to time through webcasts, conference calls, securities analyst meetings, road show presentations, investor conferences, transcripts, newsletters and similar events and communications contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws, based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of embecta may differ materially from those expressed or implied by such forward-looking statements and assumptions.These statements use words such as "will," "plan," "expect," "anticipate," "estimate," "next," "project," "potential," "continue," "expand" and "grow" and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance and statements regarding our business strategy, impact of mergers and acquisitions,future product development, regulatory clearances and approvals, competitive position and expenditures.These statements are based on current assumptions and expectations of future events at the time they are made and thus are inherently subject to uncertainty.

    All such statements are based upon current expectations of embecta and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Many of these risks and uncertainties are beyond the company's control. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. embecta expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.